MINIject (MIGS)

MINIjectTM is designed to significantly reduce IOP by enhancing aqueous humour outflow from the anterior chamber to the suprachoroidal space. Implantation is predictable in a single-step procedure using a deployment wheel.

MINIject made of STAR material
MINIject implanted in suprachoroidal space

MINIject exhibits all the advantages of the STAR® material such that it conforms to the eye anatomy, and benefits from sustained drainage efficacy over time due to bio-integration of surrounding tissues into the material. A natural flow speed results, which reduces the incidence of fibrosis, minimises scarring, and increases implant durability.

The MINIject first-in-human STAR-I clinical trial showed that the implantation of MINIject resulted in an average of over 40% IOP reduction to a mean of 13.8 mmHg at two years post-surgery. In addition, around half of patients were able to discontinue topical medication usage and remained medication-free at two years. There were no serious adverse events related to the device or the procedure, and no patient required additional glaucoma surgery. The STAR-II European trial showed consistent results at 6-month follow-up.